GSK's Votrient Gains Conditional EU Approval For Renal Cell Carcinoma
This article was originally published in The Pink Sheet Daily
Executive Summary
Regulators still want to see how GlaxoSmithKline's pazopanib compares with Pfizer's sunitinib
You may also be interested in...
Biogen's Fampyra Gains Conditional Approval In Europe
Biogen must prove additional drug benefits in further study to gain full approval.
Biogen's Fampyra Gains Conditional Approval In Europe
Biogen must prove additional drug benefits in further study to gain full approval.
RCC Market Snapshot: In A Crowded Field, What's Next?
Just five years ago, the treatment options for patients with advanced kidney cancer were limited, but today, the market for renal cell carcinoma drugs is one of the most crowded in the oncology field, with six targeted agents on the market and more on the way